Incyte company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

incyte.com

Founded Year

1991

Stage

IPO | IPO

Date of IPO

11/5/1993

Market Cap

16.73B

Stock Price

74.80

Revenue

$0000 

About Incyte

Incyte seeks to build a product pipeline of small molecule drugs.

Incyte Headquarter Location

1801 Augustine Cut-off

Wilmington, Delaware, 19803,

United States

855-463-3463

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Incyte Patents

Incyte has filed 567 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Transcription factors
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/31/2019

5/10/2022

Monoclonal antibodies, Experimental cancer drugs, Clusters of differentiation, G protein coupled receptors, Transcription factors

Grant

Application Date

10/31/2019

Grant Date

5/10/2022

Title

Related Topics

Monoclonal antibodies, Experimental cancer drugs, Clusters of differentiation, G protein coupled receptors, Transcription factors

Status

Grant

Latest Incyte News

Every-other-week dose of dupilumab safe, effective over long term

May 12, 2022

Beck LA, et al. 2022;doi:10.1007/s40257-022-00685-0. Disclosures: Beck reports being an investigator and/or consultant for AbbVie, Allakos, Arena Pharmaceuticals, AstraZeneca, Benevolent AI, DermTech, Galderma, Incyte, Janssen, Kiniksa Pharmaceuticals, LEO Pharma, Lilly, Novartis, Numab Therapeutics, Pfizer, Principia Biopharma, RAPT Therapeutics, Regeneron Pharmaceuticals, Ribon Therapeutics, Sanofi, Sanofi-Aventis, Stealth BioTherapeutics and Union Therapeutics; and owning stock in 3M, Gilead, Medtronic and Moderna. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS Back to Healio We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio A dosing change from once a week to every other week did not diminish the long-term efficacy or safety of dupilumab in certain patients with atopic dermatitis, according to analysis findings. “Moderate to severe atopic dermatitis (AD) often requires long-term management with systemic therapies,” Lisa A. Beck, MD, of the department of dermatology at the University of Rochester Medical Center in Rochester, New York, and colleagues wrote. The interim analysis evaluated the findings of an open-label extension study investigating the safety and efficacy of a change in dosing schedule of dupilumab (Dupixent, Sanofi Genzyme/Regeneron) in this patient population. Participants transitioned from weekly dupilumab 300 mg to a dose every other week. The analysis included 2,677 enrolled and treated patients. Beck and colleagues reported that 352 of those patients completed efficacy assessments through week 204, while 202 completed follow-up safety assessments through week 244. Patients complied with treatment at a rate of 98.1%, according to self-reported data. There were no changes in the safety profile of dupilumab as compared with previous trials. Nasopharyngitis, AD, upper respiratory tract infections, oral herpes, conjunctivitis, injection-site reactions and headaches each occurred in 5% or fewer patients. Efficacy results from week 204 showed that mean EASI scores were 2.46 (standard deviation [SD], ± 3.98), which the researchers noted was a 91.07% change from parent study baseline. Pruritis Numerical Rating Scale scores were 2.1 (SD, ± 1.83), which represented a mean percent change from the parent study baseline of 68.74%. Among 226 patients who transitioned from once-weekly to every-other-week dosing, efficacy of dupilumab was maintained. The open-label nature of the study, along with the lack of a control arm, may limit the applicability of these findings. In addition, a smaller subset of patients received the approved every-other-week dose. “These results support dupilumab as continuous long-term treatment for adults with moderate to severe AD,” the researchers concluded. Read more about

Incyte Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Incyte Rank

  • When was Incyte founded?

    Incyte was founded in 1991.

  • Where is Incyte's headquarters?

    Incyte's headquarters is located at 1801 Augustine Cut-off, Wilmington.

  • What is Incyte's latest funding round?

    Incyte's latest funding round is IPO.

  • Who are the investors of Incyte?

    Investors of Incyte include SV Health Investors.

  • Who are Incyte's competitors?

    Competitors of Incyte include Five Prime Therapeutics, Carmot Therapeutics, Metabolon, Tizona Therapeutics, Promentis Pharmaceuticals and 15 more.

You May Also Like

Trana Discovery Logo
Trana Discovery

Trana Discovery, a drug discovery technology company, aims to help its partners find classes of drugs for the treatment of serious viral, fungal, and bacterial infectious diseases. The technology identifies compounds that work through a mechanism of action: inhibition of the target pathogen's ability to use transfer RNA (tRNA) essential for protein synthesis or replication. The use of Trana Discovery technology can unlock the value " scientific, human, and financial " hidden in drug compound libraries, expedite the discovery of drugs, and provide opportunities for exclusive rights to drug classes.

A
Amura

Amura is a structure-based drug discovery business specialising in diseases such as osteoporosis, bone metastasis, autoimmunity, chronic pain and malaria. Amura has a scaffold (AMcore) that aims to provide a turnkey solution for the discovery of small-molecule inhibitors against cysteine peptidases (e.g. cathepsin enzymes); which are commercially attractive therapeutic targets

W
Welichem Biotech

Welichem Biotech Inc. ("Welichem", TSX-V: WBI) is engaged in the discovery and development of small molecule therapeutics. Using its Symbiochem technology platform, the Company has developed a robust pipeline of patent-protected compounds that target autoimmune/inflammatory diseases and cancers. Welichem's lead drug candidate, WBI-1001, targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. A phase I clinical trial of WBI-1001, done in Montreal, in patients with psoriasis has shown a very good safety profile and promising efficacy. As well, the application of WBI-1001 cream against atopic dermatitis (a type of eczema) in a phase IIa clinical trial also has been completed in Canada, with the final report pending in the third quarter of 2008. Welichem plans to all the necessary Phase II Clinical Trials against psoriasis and eczema in the near future. In the company's pipeline, WBI-1001 related compounds are being evaluated also for their therapeutic potential against other autoimmune diseases such as, inflammatory bowel disease and rheumatoid arthritis. Welichem's other lead drug candidate, WBI-2100, selectively targets certain types of hard-to-treat cancerous tumours. This is achieved in part through inhibition of angiogenesis and metastasis. Animal tests have shown that WBI-2100 is effective as a monotherapy and also in increasing the effectiveness of several commonly used chemotherapeutic products. The uniqueness of this small molecule cancer chemotherapeutic is that in pre-clinical studies it increases the number of neutrophils in the peripheral blood. The boosting of neutrophils in animal studies in the presence of the cancer therapeutic, cyclophosphamide, supports its potential therapeutic application for chemotherapy induced neutropenia. With its proven Symbiochem; technology platform, Welichem will advance its pipeline of drug candidates at a rate and time commensurate with resources and target need, and is in a strong position to contribute effectively to productive drug discovery and development partnerships.

A
Active Pass Pharmaceuticals

Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.

B
BioNucleon

Bionucleon is a drug discovery company with a technology platform to produce olibo-based therapeutics. Bionucleon's business strategy is based on a three-branch approach:nnUsing its technology, the company aims to build its own pipeline of therapeutics for inflammatory diseases and angiogenic disorders. Bionucleon collaborates with pharmaceutical and biotechnology companies to create new oligo-based therapeutics against targets of the partner's choosing. Bionucleon generates products for out-licensing at different research and development stages. Collaborative partnerships and out-licensing provide upfront and milestone payments, and generate downstream revenue through product royalties. This approach maximizes the return on the company's nknow-how and technical capability. Through drug discovery partnering in addition to developing its own product pipeline, Bionucleon aims to build corporate value and aims to reduce the financial risk as it moves forward.

H
Heptares Therapeutics

Heptares Therapeutics focuses on the discovery and development of novel drugs acting at G-protein coupled receptors (GPCRs). Heptares StaR (Stabilized Receptor) technology enables thermo-stabilization of GPCRs, a breakthrough allowing X-ray crystallography of conformationally-constrained receptors, thereby facilitating structure-based drug design at GPCRs that have been resistant to traditional methods of drug screening.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.